retatrutide clinical trial results weight loss 2024 2025 press release Results: 28.3% Data Retatrutide vs. Tirzepatide for Weight

Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: a randomized controlled trial

Romosozumab carries a black box warning for increased cardiovascular risk, including heart attack, stroke, and cardiovascular death

7583% achieved 15% 26% of participants on 12 mg achieved 30% weight reduction Cardiometabolic Parameters Improvements in blood pressure, HbA1c, fasting glucose, insulin, LDL-cholesterol 72% of patients with prediabetes achieved normoglycemia Safety Most common adverse events: gastrointestinal (nausea, diarrhea, constipation) , dose-dependent, predominantly mild to moderate Heart rate: slight increase up to week 24, then decrease No severe hypoglycemia, medullary carcinoma, or C-cell hyperplasia Conclusions Retatrutide induced significant, dose-dependent weight reduction of up to 24.2% over 48 weeks

Pull the plunger back to your target unit number, drawing air into the syringe equal to the volume you intend to withdraw

This decrease in energy expenditure makes continued weight loss more difficult

Effects of curcumin-related compounds on GPR55 activation We compared the activation of GPR55 by curcumin with the minor curcuminoids demethoxycurcumin and bisdemethoxycurcumin, the reduced metabolite tetrahydrocurcumin, and the conjugate curcumin -d-glucuronide, which are present in vivo upon consumption of turmeric containing foods (Fig